Index to Volume 1

Author Index

Abrams J: Commentary on nifedipine, 90
Amerson AB: Commentary on temazepam, 12
Antman EM: *see* Mueller HS et al, 78
Antman EM: *see* Rayment CM, et al, 198
Apgar DA: Metronidazole in anaerobic bacterial infections (letter), 212

Butler CD: *see* Lackner TE, et al, 212

Cody RJ: Commentary on timolol, 197
Crismon ML: Commentary on amoxapine, 177

DeVane CL: Commentary on temazepam, 12
DiPiro JT: Commentary on sulfamethoxazole-trimethoprim, intravenous, 211
Donlon PT: Commentary on amoxapine, 176
Dunn FG, Frohlich ED: Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent, 188

Evans WE: *see* Yee GC et al, 55

Feingold DS: Commentary on topical clindamycin, 204
Ferst JA: *see* Mueller HS et al, 78
Frank MSB, Nahata MC, Hilty MD: Glycerol: a review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use, 147
Frohlich ED: *see* Dunn FG, et al, 188

Gantz NM: *see* Gleckman R, et al, 206
Gelenberg AJ: *see* Lydiard RB, et al, 163
Gelenberg AJ: *see* Wells BG et al, 121
Gleckman R, Blagg N, Joubert DW: Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications, 14
Gleckman R, Gantz NM, Joubert DW: Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions, 206

Hekimian LJ: Commentary on amoxapine, 175
Hills JR: *see* Scheife RT et al, 39
Hilty MD: *see* Frank MSB et al, 147

Ingalls KK: Commentary on amoxapine, 176

Jick H: *see* Porter JB et al, 160
Joubert DW: *see* Gleckman R, et al, 206

Kellner R: Commentary on amoxapine, 175
Kelly KL: Commentary on timolol, 198
Kramer M: *see* Scharf MB et al, 13

Labreche DG: Commentary on nifedipine, 91
Lackner TE, Butler CD: Metronidazole in anaerobic bacterial infections (letter), 212
Lesko LJ: Commentary on sulfamethoxazole-trimethoprim, intravenous, 211
Longenecker RG: Commentary on maprotiline, 138
Lowenthal DT: Commentary on amiloride, 187
Lydiard RB, Gelenberg AJ: Amoxapine — an antidepressant with some neuroleptic properties?, 163

Miller RR: A new journal (editorial), 1
Miller RR: Editor's note on timolol, 200
Miller RR: Evaluation of the analgesic efficacy of ibuprofen, 21
Miller RR: Two new series (editorial), 77
Misbin RI: *see* Santen RJ et al, 95
Mitler RR: Evaluation of temazepam as a hypnotic, 3
Mueller HS, Antman EM, Ferst JA, Muller JE: Nifedipine in the treatment of cardiovascular disease, 78
Muller JE: *see* Mueller HS et al, 78
Munsat TL: *see* Scheife RT et al, 39

Nahata MC: *see* Frank MSB et al, 147

Parkinson DR: Commentary on aminoglutethimide, 120
Perry PJ: Commentary on maprotiline, 139
Pishkin V: Commentary on temazepam, 12
Pochi PE: Commentary on topical clindamycin, 204
Ponte CD: Commentary on trimethoprim, 20
Porter JB, Jick H, Ylvisaker JT: Malignant liver tumor associated with oral contraceptive use, 160

Rayment CM, Antman EM: Commentary on timolol, 198
Regestein QR: Commentary on temazepam, 11
Rehder TL: Commentary on amiloride, 186
Resnick RB: *see* Washton AM et al, 140
Rosen T, Waisman M: Topically administered clindamycin in the treatment of acne vulgaris and other dermatologic disorders, 201

Salem DN: Commentary on nifedipine, 91
Salhanick HA: Commentary on aminoglutethimide, 119
Santen RJ, Misbin RI: Aminoglutethimide: review of pharmacology and clinical use, 95
Scharf MB, Kramer M: Commentary on temazepam, 13
Schatzberg AF: Commentary on maprotiline, 139
Scheife RT, Hills JR, Munsat TL: Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy, 39
Steiner GA: Commentary on temazepam, 12
Stimmel GL: Commentary on amoxapine, 177
Sullivan CE: *see* Tally FP et al, 28
Sullivan CE: *see* Tally FP, et al, 212
Sullivan JM: Commentary on amiloride, 186

Tally FP, Sullivan CE: Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections, 28
Tally FP, Sullivan CE: Metronidazole in anaerobic bacterial infections (letter), 212
Tannenbaum RP: Commentary on timolol, 197

Vidt DG: Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic, 179

Waisman M: *see* Rosen T, et al, 201
Washton AM, Resnick RB: Clonidine in opiate withdrawal: review and appraisal of clinical findings, 140
Wells BG, Gelenberg AJ: Chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of the antidepressant maprotiline hydrochloride, 121
Wells SA Jr: Commentary on aminoglutethimide, 120
West DP: Commentary on topical clindamycin, 205

Yee GC, Evans WE: Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides, 55
Ylvisaker JT: *see* Porter JB, 160

Subject Index

Acebutolol, comparison with timolol, 189
Adrenal corticosteroids, use in myasthenia gravis, 49
Aldactazide (spironolactone + hydrochlorothiazide), comparison with Moduretic (amiloride + hydrochlorothiazide), 182
Alprenolol, comparison with timolol, 189
Ambenonium chloride, use in myasthenia gravis, 46
Amikacin, *see* aminoglycosides, 55
Amiloride, mechanisms of action, 179; pharmacokinetics, 180; adverse effects, therapeutic uses, use as a potassium-sparing agent, 181; use as a diuretic-antihypertensive, use in hypertensive patients with aldosterone excess, 184; use in the management of fluid retention, 182
Aminoglutethimide, pharmacology, inhibitory effects on steroidogenesis, 96; effects on enzyme induction, effects on thyroxine synthesis, clinical pharmacology, adrenal inhibition, 98; aromatase inhibition, 102; effects on androgen secretion, effects on aldosterone secretion, inhibition of ovarian function, 103; inhibition of thyroid function, bioavailability, metabolism, 105; use in Cushing's syndrome, 106; use in breast carcinoma, 108; adverse effects, 113; practical consideration in use, 115
Aminoglycosides, pharmacokinetic monitoring, 55; relationship between serum concentrations and therapeutic response, 56; relationship between serum concentrations and nephrotoxicity, 58; relationship between serum concentrations and ototoxicity, 64; rationale for pharmacokinetic monitoring, use in patients with normal renal function, 66; use in patients with altered absorption, 67; use in obese patients, use in patients with altered renal function, 68; use in neonates, 69; use in infants and children, 70
Amoxapine, chemistry, animal pharmacology and toxicology, neurochemical actions, behavioral effects, 164; cardiovascular effects, autonomic nervous system effects, absorption, metabolism, excretion, 165; toxicity in animals, effects on reproduction and teratology in animals, human pharmacology, clinical efficacy, 166; open trials, 167; comparison with amitriptyline, 168; comparison with imipramine, adverse effects, serum concentrations, 170; teratogenicity in man, onset of action, 173; neuroleptic effects, blocking action on dopamine receptor, 174
Anti-receptor antibody titers, use in myasthenia gravis, 46
Asendin (Lederle), *see* amoxapine, 163
Atenolol, comparison with timolol, 189

Blocadren (Merck Sharp & Dohme), *see* timolol maleate, 188

Cleocin T (Upjohn), *see* clindamycin, topical, 201
Clindamycin, oral, use in acne vulgaris, 201
Clindamycin, topical, delivery systems, extemporaneous preparation, use in acne vulgaris, 202; adverse effects, use in erythrasma, rosacea, periorificial dermatitis, folliculitis, 203
Clonidine, use in opiate withdrawal, detoxification trials, 141; single-dose trials, 142
Correction notice, Clonidine in opiate detoxification, 214
Curare, use in myasthenia gravis, 45
Cytadren (Ciba-Geigy), *see* aminoglutethimide, 95

Dyazide (triamterene + hydrochlorothiazide), comparison with Moduretic (amiloride + hydrochlorothiazide), 182

Edrophonium, use in myasthenia gravis, 44, 46
Electrophysiologic testing, use in myasthenia gravis, 45

Flagyl (Searle), *see* metronidazole, 28

Gentamicin, *see* aminoglycosides, 55
Glycerol, biochemical pharmacology, 148; pharmacokinetics, 149; adverse reactions, 150; use in Reye's syndrome, use in stroke, 153; use in pseudotumor cerebri, use in meningitis and encephalitis, 154; use in central nervous system tumors, space occupying lesions, and neurosurgical procedures, 155; use in central nervous system trauma, use in central nervous system asphyxia, use in glaucoma, 156; use in hepatic coma, use in diabetes mellitus, preparation, 157

Ibuprofen, clinical pharmacology, 21; analgesic efficacy, 22; use in dental pain, dysmenorrhea, episiotomy pain, postsurgical pain, and other types of pain, 24; relative potency, time course of analgesia, adverse effects, dosage, cost, 25
I.V. Bactrim (Roche), *see* sulfamethoxazole-trimethoprim, intravenous, 206
I.V. Septra (Burroughs-Wellcome), *see* sulfamethoxazole-trimethoprim, intravenous, 206

Kanamycin, *see* aminoglycosides, 55

Liver tumor, malignant, 160
Lofexidine, use in opiate withdrawal, 143
Ludiomil (Ciba-Geigy), *see* maprotiline hydrochloride, 121

Maprotiline hydrochloride, biochemical and neuropharmacological effects, chemistry, 121; cardiovascular effects, 123; other effects, pharmacokinetics, adverse effects, 124; interaction with other drugs, 126; overdosage, precautions, 127; efficacy in open trials, 128; efficacy in double-blind trials, 129; time course for antidepressant effects, 133; dosage and administration, 134
Metoprolol, comparison with timolol, 189
Metronidazole, mechanism of action, 29; pharmacokinetic properties, 30; adverse reactions, 31; carcinogenicity, 32; therapeutic use in trichomonal vaginitis, non-specific vaginitis, amebiasis, giardiasis, anaerobic bacterial infections, 33; therapeutic use in nervous system infections, intraabdominal infections, 34; therapeutic use in obstetrical and gynecological infections, endocarditis, prophylactic use for anaerobic surgical infections, 35
Midamor (Merck Sharp & Dohme), *see* amiloride, 179
Moducren (amiloride + hydrochlorothiazide + timolol), therapeutic uses, 184
Moduretic (amiloride + hydrochlorothiazide), therapeutic uses, 182
Motrin (Upjohn), *see* ibuprofen, 21
Myasthenia gravis, history, epidemiology, clinical presentation, 40; etiology and pathogenesis, 41; diagnosis, use of repetitive motor activity test, 43; use of Tensilon (edrophonium) test, 44; use of curare test, electrophysiologic testing, 45; use of anti-receptor antibody titers, treatment with anticholinesterase agents, 46; treatment with adrenal corticosteroids, 49; treatment with immunosuppressant therapy, drug-induced, 52

Nadolol, comparison with timolol, 189
Neostigmine bromide, use in myasthenia gravis, 46
Neostigmine methylsulfate, use in myasthenia gravis, 46
Nifedipine, mechanisms of action, effects on calcium ion fluxes, effects on the cardiovascular system, 79; effects on the coronary vascular bed, 80; effect on contractility and peripheral vascular beds, 81; comparison with nitrates of hemodynamic effects, pharmacokinetic properties, use in variant angina pectoris, 83; use unstable angina pectoris, use in chronic stable angina pectoris, 84; comparison with other antianginal agents, use in hypertension, 85; other uses, adverse effects, dosage, 86; use in effort angina pectoris, use in unstable angina pectoris, use in hypertension, use in heart failure, adverse effects, 92

Oral contraceptive, associated with malignant liver tumor, 160
Oxprenolol, comparison with timolol, 189

Pindolol, comparison with timolol, 189
Prednisone, use in myasthenia gravis, 49
Procardia (Pfizer), *see* nifedipine, 78
Proloprim (Burroughs Wellcome), *see* trimethoprim, 14
Propranolol, comparison with timolol, 189
Pyridostigmine bromide, use in myasthenia gravis, 46

Restoril (Sandoz), *see* temazepam, 9

Sulfamethoxazole-trimethoprim, intravenous, pharmacokinetic properties, dosage and administration, 207; use in *Pneumocystis carinii* pneumonia, the infected cancer patient, bacterial intestinal infections, 208; use in meningitis, surgical prophylaxis, adverse reactions, 209

Temazepam, chemistry, physical properties, preparations, dosage, pharmacokinetics, metabolism, 3; pharmacology, hypnotic efficacy, 4; safety, 8; precautions, 9
Timolol maleate, pharmacology and pharmacokinetics, 188; mechanisms of action, 190; antihypertensive action, 191; action in glaucoma, antiarrhythmic action, action in migraine, use in ischemic heart disease, protective effect in myocardial infarction, 192; use in hypertension, 193; use in arrhythmias, use in glaucoma, 194; use in migraine, adverse effects, 195
Tobramycin, *see* aminoglycosides, 55
Trimethoprim, mechanism of action, 14; antimicrobial activity, mechanisms of resistance, clinical studies of resistance, 15; pharmacokinetics, alteration of laboratory tests, dosage, adverse reactions, 16; efficacy in urinary tract infections and other infections, therapeutic indications, 17
Trimpex (Roche), *see* trimethoprim, 14